Datapoint: Roche Scores Expanded SMA Nod for Evrysdi

The FDA this week approved Roche’s at-home spinal muscular atrophy (SMA) therapy Evrysdi in children under two months old. The treatment was first approved for SMA in adults and older children in August 2020. It currently holds covered or better status for 81% of all insured lives under the pharmacy benefit.

SOURCE: MMIT Analytics, as of 6/1/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 22

Datapoint: Baystate to Sell Health Plan to Point32Health

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 21

Datapoint: Cigna, HelloFresh Partner on Meal Kit Benefits

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 20

Datapoint: SCAN, CareOregon Nix Merger Plans

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today